NCT04442711Recruiting
Cohort of IPF Patients Experiencing an Exacerbation
Pulmonary Fibrosis Biomarkers During Exacerbation
Source: ClinicalTrials.gov · Last updated 22 Dec 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years. In the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 13 Jun 2020
- Start date
- 13 Jun 2020
- Primary completion date
- 1 Dec 2027
- Lead sponsor
- University Hospital, Gentofte, Copenhagen
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT04442711
What you commit to
- Study type: Observational
- Planned participants: 50
- From 13 Jun 2020 to the primary completion date, 1 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable to provide informed consent
Who the study is looking for
- Admitted with an increase in respiratory symptoms
- Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA
- Age at least 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Herlev and Gentofte Hospital Coordinator of this site? Confirm its status | Hellerup | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.